Plain-English translation of NCT06830629 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase 2 clinical trial testing a new medication called in adults with chronic kidney disease who have a particular genetic marker (called APOL1 high-risk genotype) and protein in their urine. Researchers want to understand whether the medication is safe to take and whether it can reduce the amount of protein being lost through the kidneys. The study will include people with kidney disease who also have diabetes, as well as those who don't.
Certain genetic variations make some people's kidneys more vulnerable to disease and damage. This medication is being tested to see if it can specifically help people with this genetic risk by slowing the progression of their kidney disease and reducing the harmful protein loss that damages kidneys over time.
You likely qualify if…
You likely don't qualify if…
You would take the medication as part of this open-label study, meaning you and your doctors will know you're receiving the active treatment (not a placebo). Throughout the study, you'll have regular clinic visits where researchers will check your kidney function, measure protein levels in your urine, and monitor how well you're tolerating the medication. The study will look at whether the treatment is safe and whether it helps reduce the protein being lost through your kidneys.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States